[P1–044]: SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER's DISEASE DEMENTIA
Christopher Carlson(Eli Lilly (United States)), Eric Siemers(Eli Lilly (United States)), David Pérahia(École Normale Supérieure Paris-Saclay), Greg Anglin(Eli Lilly (Canada)), Brenda Crowe(Eli Lilly (United States)), Gopalan Sethuraman(Eli Lilly (United States)), R. Yaari(Eli Lilly (United States)), Sherie A. Dowsett(Eli Lilly (United States)), Ludmila Kryzhanovskaya, Rashna Khanna(Eli Lilly (United States)), Michael Case(Eli Lilly (United States)), Ann Marie Hake(Eli Lilly (United States))
Cited by 1
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
|Alzheimer s & Dementia|2011|830
On the path to 2025: understanding the Alzheimer’s disease continuum
|Alzheimer s Research & Therapy|2017|559